Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Oportuzumab monatox |
Synonyms | |
Therapy Description |
Oportuzumab monatox (VB4-845) comprises an EpCAM-targeted monoclonal antibody fragment linked to Pseudomonas endotoxin A, which may result in decreased protein synthesis in EpCAM-expressing tumor cells (PMID: 31847708). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Oportuzumab monatox | VB4-845|Vicinium|Proxinium | Oportuzumab monatox (VB4-845) comprises an EpCAM-targeted monoclonal antibody fragment linked to Pseudomonas endotoxin A, which may result in decreased protein synthesis in EpCAM-expressing tumor cells (PMID: 31847708). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02449239 | Phase III | Oportuzumab monatox | Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG | Completed | USA | CAN | 0 |